Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Pulmonology · Nonspecific Interstitial Pneumonia

Why Does Multidisciplinary Review Matter for NSIP Diagnosis?

At a Glance

A multidisciplinary discussion improves NSIP diagnosis by bringing lung, scan, tissue, autoimmune, and exposure experts together. Because NSIP is a lung-injury pattern rather than a single cause, the team compares all evidence before choosing a diagnosis and care plan.

A multidisciplinary discussion (MDD) is the recommended standard approach for diagnosing interstitial lung diseases (ILDs) like Non-Specific Interstitial Pneumonia (NSIP). Because a single test or specialist rarely tells the whole story, an MDD brings together experts from different fields to review your symptoms, scans, bloodwork, and biopsy results [1][2]. This collaborative approach improves diagnostic confidence and helps tailor your care plan [3][4].

NSIP Is a Pattern, Not a Cause

The most important reason for a team approach is that “NSIP” describes a specific pattern of lung injury seen on a scan or under a microscope—it is not an underlying cause on its own [5][6]. The same or a very similar pattern can be associated with:

  • Undiagnosed autoimmune diseases (such as rheumatoid arthritis, scleroderma, or myositis)
  • Certain medications or treatments
  • Exposures to molds, birds, or workplace dusts (which typically cause hypersensitivity pneumonitis but can sometimes mimic an NSIP pattern)
  • An “idiopathic” disease, meaning the cause remains unknown after a thorough investigation

To figure out why you have this pattern, your medical team must piece together clues from multiple sources [6]. Research shows that an MDD review can substantially change a patient’s initial diagnosis or management plan [7][5].

Who Is on the Multidisciplinary Team?

Each specialist brings a critical piece to the puzzle. They usually review your records in a conference setting and then your lead doctor will discuss the findings with you.

The ILD Pulmonologist

The pulmonologist (lung specialist) coordinates the evaluation. They present your complete medical story, including your symptoms, how your disease has changed over time, your medications, and your breathing test (PFT) results [1][2]. They integrate the findings from all other specialists to recommend an individualized care plan [1].

The Thoracic Radiologist

A radiologist who specializes in chest imaging examines your High-Resolution Computed Tomography (HRCT) scans. The classic NSIP pattern often shows “ground-glass” (haziness) and fine web-like scarring (reticulation) in the lower lungs, usually with little to no “honeycombing” (clusters of cysts) [6][8]. However, because ground-glass and reticulation can occur in many lung diseases, the radiologist must interpret these images in the context of your overall health [6][9].

The Pulmonary Pathologist

If you had a surgical lung biopsy, a specialized pathologist examines your lung tissue under a microscope. An NSIP pattern typically shows “temporally uniform” injury, meaning the inflammation and scarring appear to be the same age across the sample [6][10]. The pathologist helps confirm the pattern but cannot usually determine the cause—like an autoimmune disease or drug reaction—on their own [10].

Note on Biopsies: Many patients can be diagnosed without an invasive biopsy if their scans and clinical history are clear enough [11]. Biopsies carry meaningful risks and are usually only recommended if the results would change your treatment [5][1].

Consulting Specialists: Rheumatology and Occupational Medicine

Depending on your specific case, other experts may be brought in or consulted:

  • Rheumatologist: Autoimmune-associated lung disease can sometimes be the very first sign of a condition, even before obvious symptoms appear [12][13]. A rheumatologist looks for subtle signs—like Raynaud’s (fingers turning white/blue in the cold), dry eyes/mouth, or unexplained fevers—and runs specialized blood panels [13].
  • Occupational/Environmental Specialist: This expert explores your lifetime history of jobs, hobbies, and home environments. Discovering a hidden exposure to birds, mold, or workplace chemicals can sometimes change the diagnosis and management [14].

Why Do Diagnoses Sometimes Remain “Unclassifiable”?

Even with a full team, some cases are labeled as “unclassifiable.” This happens when your test results point in different directions or when there simply isn’t enough information to be certain [15][16].

A common challenge is sampling limitation during a biopsy. If your tissue sample is too small, crushed, or not representative of patchy disease, the pathologist may not be able to identify a clear pattern [10][17]. Additionally, overlapping features on scans and pathology can make it impossible to pin down one definitive label [15].

When this happens, the MDD will give you a “working” or “provisional” diagnosis. This allows the team to create a care plan—which might include monitoring, removing a suspected exposure, or starting medication—and they will re-evaluate your case as your condition evolves [5].

What to Bring for a Second Opinion

If you are seeking a second opinion or an MDD review at a specialized ILD center, you need to provide the complete picture. Contact the new center first, as many hospitals transfer these records electronically:

  • Original scan files: The thoracic radiologist needs to look at the original CT images (often called DICOM files), including all past scans to see how your lungs have changed [1].
  • Pathology slides: If you had a biopsy, the new center may request the physical glass slides or tissue blocks directly from your original lab [10].
  • Complete records: Include your breathing test (PFT) results, all blood work (especially autoimmune panels), your pathology and radiology reports, and a list of all current and past medications with start dates [1][13].

Common questions in this guide

Why is a team approach useful when NSIP is suspected?
A multidisciplinary discussion allows lung, imaging, tissue, and other specialists to review the same evidence together. This is useful because an NSIP pattern can have several causes, and the combined review may change the diagnosis or care plan.
Does an NSIP scan pattern identify the cause of lung disease?
No. NSIP describes a pattern of lung inflammation and scarring seen on imaging or under a microscope, rather than the reason it developed. Doctors may look for autoimmune disease, medication effects, environmental exposures, or an unexplained cause.
Which specialists can help evaluate possible NSIP?
An ILD pulmonologist usually coordinates the evaluation, while a thoracic radiologist reviews chest scans and a pulmonary pathologist reviews biopsy tissue when available. A rheumatologist or occupational and environmental specialist may also help identify autoimmune disease or relevant exposures.
Is a surgical lung biopsy required for every NSIP diagnosis?
No. Some people can be diagnosed without surgery when their symptoms, medical history, blood tests, and high-resolution CT findings fit together clearly. Because a biopsy is invasive and has risks, it is usually considered only when the result could change management.
What happens if doctors cannot classify my NSIP pattern?
It means the available evidence does not support one definite diagnosis, often because results conflict or a tissue sample is too small or unrepresentative. The team can use a provisional diagnosis to guide monitoring or treatment and revisit it as the condition changes.
What records should I provide for an ILD second opinion?
Provide original CT image files, including older scans, and ask how the center wants to receive any biopsy slides or tissue blocks. Send pulmonary function tests, blood work, radiology and pathology reports, and a complete list of current and past medications with start dates.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Non-specific interstitial pneumonia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my case been reviewed by a formal multidisciplinary team, and if so, who was involved?
  2. 2.Were there any disagreements among the specialists about my diagnosis, and how were they resolved?
  3. 3.Did the radiologist or pathologist see any features that suggest an autoimmune disease or an environmental exposure?
  4. 4.Based on the team's review, how confident are you in my diagnosis, or is it considered a 'working' diagnosis?
  5. 5.Would a biopsy help clarify my diagnosis, and do the benefits outweigh the risks in my specific case?

References

References (17)
  1. 1

    Role of Multidisciplinary Team Meetings in the Diagnosis and Management of Diffuse Parenchymal Lung Diseases in a Tertiary Care Hospital.

    Khan MA, Sherbini N, Alyami S, et al.

    Avicenna journal of medicine 2023; (13(4)):230-236 doi:10.1055/s-0043-1776063.

    PMID: 38144909
  2. 2

    Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).

    Jee AS, Adelstein S, Bleasel J, et al.

    Journal of clinical medicine 2017; (6(5)) doi:10.3390/jcm6050051.

    PMID: 28471413
  3. 3

    Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study.

    Walsh SLF, Wells AU, Desai SR, et al.

    The Lancet. Respiratory medicine 2016; (4(7)):557-565 doi:10.1016/S2213-2600(16)30033-9.

    PMID: 27180021
  4. 4

    Histologist's original opinion compared with multidisciplinary team in determining diagnosis in interstitial lung disease.

    Burge PS, Reynolds J, Trotter S, et al.

    Thorax 2017; (72(3)):280-281 doi:10.1136/thoraxjnl-2016-208776.

    PMID: 27815523
  5. 5

    Diagnostic approach of fibrosing interstitial lung diseases of unknown origin.

    Cottin V, Valenzuela C

    Presse medicale (Paris, France : 1983) 2020; (49(2)):104021 doi:10.1016/j.lpm.2020.104021.

    PMID: 32437843
  6. 6

    Idiopathic non-specific interstitial pneumonia.

    Belloli EA, Beckford R, Hadley R, Flaherty KR

    Respirology (Carlton, Vic.) 2016; (21(2)):259-68 doi:10.1111/resp.12674.

    PMID: 26564810
  7. 7

    Multidisciplinary management of interstitial lung diseases: A real-life study.

    Biglia C, Ghaye B, Reychler G, et al.

    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2019; (36(2)):108-115 doi:10.36141/svdld.v36i2.8107.

    PMID: 32476943
  8. 8

    Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 3. Idiopathic Nonspecific Interstitial Pneumonia.

    Lee J, Kim YH, Kang JY, et al.

    Tuberculosis and respiratory diseases 2019; (82(4)):277-284 doi:10.4046/trd.2018.0092.

    PMID: 31172700
  9. 9

    Pathological features of connective tissue disease-associated interstitial lung disease in transbronchial cryobiopsies.

    Churg A, Poletti V, Ravaglia C, et al.

    Histopathology 2025; (86(2)):260-267 doi:10.1111/his.15311.

    PMID: 39223069
  10. 10

    A Brief Guide to Interpreting Transbronchial Cryobiopsies for Diffuse Parenchymal Lung Disease.

    Churg A, Wright JL, Manchen P, et al.

    The American journal of surgical pathology 2025; (49(10)):1068-1077 doi:10.1097/PAS.0000000000002424.

    PMID: 40396574
  11. 11

    Interstitial lung disease pathology in systemic sclerosis.

    Konopka KE, Myers JL

    Therapeutic advances in musculoskeletal disease 2021; (13()):1759720X211032437 doi:10.1177/1759720X211032437.

    PMID: 34349846
  12. 12

    Autoantibodies in interstitial lung diseases.

    Stevenson BR, Thompson GA, Watson MC, et al.

    Pathology 2019; (51(5)):518-523 doi:10.1016/j.pathol.2019.03.007.

    PMID: 31230817
  13. 13

    A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia.

    Chartrand S, Swigris JJ, Peykova L, et al.

    The Journal of rheumatology 2016; (43(5)):887-92 doi:10.3899/jrheum.150966.

    PMID: 26932342
  14. 14

    A comprehensive assessment of environmental exposures and the medical history guides multidisciplinary discussion in interstitial lung disease.

    Dodia N, Amariei D, Kenaa B, et al.

    Respiratory medicine 2021; (179()):106333 doi:10.1016/j.rmed.2021.106333.

    PMID: 33676119
  15. 15

    Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis.

    Guler SA, Ellison K, Algamdi M, et al.

    Annals of the American Thoracic Society 2018; (15(7)):854-863 doi:10.1513/AnnalsATS.201801-067OC.

    PMID: 29779392
  16. 16

    Relative incidence of interstitial lung diseases in Brazil.

    Matias SLK, Pereira CAC, Soares MR, et al.

    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia 2024; (50(1)):e20230232 doi:10.36416/1806-3756/e20230232.

    PMID: 38536981
  17. 17

    Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study.

    Troy LK, Grainge C, Corte TJ, et al.

    The Lancet. Respiratory medicine 2020; (8(2)):171-181 doi:10.1016/S2213-2600(19)30342-X.

    PMID: 31578168

This page explains multidisciplinary evaluation of NSIP for informational purposes only and does not constitute medical advice. Your ILD team can explain how the findings apply to your diagnosis, testing, and biopsy decisions.